Found: 1
Select item for more details and to access through your institution.
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article